Last edition
News about "Innovent Biologics"
Innovent and Daiichi Sankyo Partner for Vanflyta Commercialisation in China
Innovent Biologics and Daiichi Sankyo have entered an exclusive agreement to commercialise Vanflyta in China, expanding access for FLT3-ITD positive AML patients.
Innovent Biologics | 11/08/2026 | By News Bureau
Innovent Doses First Patient in Pivotal IBI363/TAK-928 CRC Study
Innovent has dosed the first patient in its pivotal IBI363/TAK-928 study, advancing next-generation immunotherapy for colorectal cancer.
Innovent Biologics | 06/08/2026 | By News Bureau | 382
Innovent Biologics Licenses Anti-CD40L Therapy IBI355 to Spero Therapeutics in USD 1.1 Billion Deal
Innovent Biologics has licensed global rights outside Greater China for its anti-CD40L antibody IBI355 to Spero Therapeutics in a deal valued at up to USD 1.1 billion, advancing the development of a potential new treatment for autoimmune diseases including IgG4-related disease and Sjögren's disease.
Innovent Biologics | 15/07/2026 | By News Bureau | 186
Innovent and Lilly Partner to Commercialise Verzenios in China
Innovent Biologics and Eli Lilly have signed a commercialisation agreement for Verzenios (abemaciclib) in mainland China, expanding access to the CDK4/6 inhibitor for cancer patients.
Innovent Biologics | 01/07/2026 | By News Bureau
Pfizer and Innovent Biologics Partner to Advance Global Oncology Drug Development
Pfizer and Innovent Biologics have entered a global strategic collaboration to develop innovative oncology medicines, combining 12 discovery and early-stage programs to accelerate cancer drug development through shared research, clinical development, and commercialisation efforts.
Innovent Biologics | 29/05/2026 | By News Bureau | 134
Innovent Doses First Patient in Phase III Trial of Tigulixostat for Gout
Innovent initiates Phase III study of tigulixostat against febuxostat in Chinese gout patients, aiming to deliver improved uric acid control and better safety outcomes.
Innovent Biologics | 23/03/2026 | By News Bureau | 161
HeriCare-Breast01 study evaluates next-generation HER2 ADC against standard THInnovent BiologicsP regimen, following promising phase I/II efficacy and safety data presented at ASCO 2025.
Innovent Biologics | 16/02/2026 | By News Bureau | 219
Innovent Biologics and Eli Lilly Forge Strategic Collaboration in Oncology and Immunology
Innovent Biologics will receive USD 350 million upfront and up to USD 8.5 billion in milestones under a new global development pact, with Lilly securing ex-Greater China rights to novel oncology and immunology programmes.
Innovent Biologics | 10/02/2026 | By News Bureau | 173
Innovent Collaborates with Lilly to Develop New Medicines in Oncology and Immunology
The agreement grants Lilly an exclusive licence to develop and commercialise the programmes worldwide outside Greater China, while Innovent retains rights in Greater China.
Innovent Biologics | 09/02/2026 | By News Bureau | 139
Innovent Biologics’ tri-specific antibody IBI3003 has received FDA Fast Track Designation for heavily pretreated relapsed or refractory multiple myeloma, supported by promising early clinical efficacy and safety data.
Innovent Biologics | 27/01/2026 | By News Bureau | 291
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy